For social anxiety!

ArticleMedicine Guanlan

Today (November 8), the Center for Drug Evaluation (CDE) of the State Drug Administration of China announced that a PH94B nasal spray jointly declared by VistaGen Therapeutics and Shanghai Aimai Medical Technology Co.

Screenshot source: CDE official website

Public information shows that PH94B is a potential "first-in-class", odorless, and fast-acting (within 15 minutes) synthetic neurosteroid nasal spray, which has the potential to treat a variety of anxiety-related diseases

It is reported that PH94B is intended to be administered intranasally in a microgram dose, which is fundamentally different from all current anti-anxiety drugs, including benzodiazepines

Previously, PH94B has achieved positive results in phase 2 clinical studies.

In June 2020, EverInsight Inc.

In October 2020, AffaMed Therapeutics, another company also incubated by Cambridge Capital, reached a final merger agreement with EverInsight.

Social anxiety disorder is a health problem that attracts people's attention

At present, SAD usually uses certain regulatory-approved antidepressants for long-term treatment.

Reference materials:

[1] Drug Evaluation Center of China National Medical Products Administration.

[3]VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia.

[4]US FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder.